Orforglipron half-life & pharmacokinetics

Reported half-life

Approximately 29-49 hours plasma half-life supporting once-daily oral dosing. Substantially shorter than injectable GLP-1 agonists (semaglutide ~7 days, retatrutide ~6 days) because the extended half-life mechanism (fatty-acid acylation) used for peptide agonists does not apply to small-molecule pharmacology.

The half-life and pharmacokinetic profile of Orforglipron reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Oral tablet (Phase III clinical trial route)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Small-molecule non-peptide GLP-1 receptor agonist; Phase III clinical-development unlicensed compound; structurally distinct from peptide GLP-1 agonists.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Orforglipron acts as follows:

Orforglipron (Eli Lilly development code LY3502970) is a small-molecule biphenyl-based benzimidazole GLP-1 receptor agonist — structurally unrelated to native GLP-1 or peptide analogues, but engaging the same GLP-1 receptor to produce comparable downstream pharmacology. The compound is the first orally-active non-peptide GLP-1 agonist to reach Phase III registration trials, addressing the long-standing pharmacological gap between injectable peptide agonists (weekly SC dosing, high bioavailability, restrictive administration) and true small-molecule oral pharmacology (daily dosing, tablet convenience, no injection-adherence barrier).

See the full Orforglipron research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.